Abstract
Astrocytic tumors constitute the most numerous and heterogeneous group of gliomas, with an incidence estimated at 60% of all primary intracranial neoplasms. Because of the variety and complexity of astrocytic tumors, for their intraoperative study, it is advisable to divide them into two important groups: (1) diffuse astrocytic tumors, a group of widely infiltrative neoplasms –considered to be surgically incurable – that includes diffuse astrocytomas (grades II to IV), diffuse midline glioma, and gliomatosis cerebri, and (2) localized “nondiffuse” astrocytic tumors, a group of relatively circumscribed neoplasms – in which attempt of gross total resection is the treatment of choice – that includes pilocytic astrocytoma, subependymal giant cell astrocytoma, and pleomorphic xanthoastrocytoma. Therefore, distinguishing diffuse astrocytic tumors (any type) from localized “nondiffuse” astrocytic tumors (any type) during surgery remains the main goal for the improvement of treatment planning. In this chapter, the cytomorphologic features and intraoperative differential diagnosis of all these entities are reviewed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggesting Reading
Ahluwalia CK, Chandrasoma PT. Cytomorphology of subependymal giant cell astrocytoma. A case report. Acta Cytol. 1993;37:197–200.
Altermatt HJ, Scheithauer BW. Cytomorphology of subependymal giant cell astrocytoma. Acta Cytol. 1992;36:171–5.
Bleggi-Torres LF, Gasparetto EL, Faoro LN, Hanel R, et al. Pleomorphic xanthoastrocytoma. Report of a case diagnosed by intraoperative cytophatological examination. Diagn Cytopathol. 2001;24:120–2.
Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:775–88.
Chan JA, Zhang H, Roberts PS, Jozwiak S, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropath Exp Neurol. 2004;63:1236–42.
Chen YH, Gutmann DH. The molecular and cell biology of pediatric low-grade gliomas. Oncogene. 2014;33:2019–26.
Chiang JCH, Ellison DW. Molecular pathology of paediatric central nervous system tumours. J Pathol. 2017;241:159–72.
Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev. Pathol. 2014;9:1–25.
Eckel-Passow JE, Lachance DH, Molinaro AM, Kyle M, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372:2499–508.
Finkle HI. Protoplasmic astrocytoma: Cytologic features on tissue imprint preparation. Diagn Cytopathol. 1992;8:430–1.
Franz DN, Agricola K, Mays M, Tudor C, et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015;78:929–38.
Gandolfi A, Tedeschi F, Brizzi R. Cytology of giant-cell glioblastoma. Acta Cytol. 1983;27:193–6.
Gielen GH, Gessi M, Hammes J, Kramm CM, Waha A, Pietsch T. H3F3A K27 M mutation in pediatric CNS tumors. A marker of diffuse high-grade astrocytoma. Am J Clin Pathol. 2013;139:345–9.
Hayashi T, Haba R, Kushida Y, Katsuki N, et al. Pilomyxoid astrocytoma of the pineal region: cytopathological features and differential diagnostic considerations by intraoperative smear preparation. Diagn Cytopathol. 2015;43:121–4.
Hawkins C, Walker E, Mohamed N, Zhang C, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res. 2011;17:4790–8.
Ida CM, Rodriguez FJ, Burger PC, Caron AA, et al. Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol. 2015;25:575–86.
Jaiswal S, Vij M, Jaiswal AK, Srivastava AK, Behari S. Squash cytology of subependymal giant cell astrocytoma: report of four cases with brief review of literature. Diagn Cytopathol. 2012;40:333–6.
Jiménez-Heffernan JA, Freih Fraih A, Álvarez F, Bárcena C, Corbacho C. Cytologic features of pleomorphic xanthoastrocytoma, WHO grade II. A comparative study with glioblastoma. Diagn Cytopathol. 2017;45:339–44.
Kim SH, Lee KG, Kim TS. Cytologic characteristics of subependymal giant cell astrocytoma in squash smears. Acta Cytol. 2007;51:375–9.
Kim YH, Nobusawa S, Mittelbronn M, Paulus W, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177:2708–14.
Kobayashi S. Meningioma, neurilemmoma and astrocytoma specimens obtained with the squash method for diagnosis. Acta Cytol. 1993;37:913–2.
Kobayashi S, Hirakawa E, Haba R. Squash cytology of pleomorphic xanthoastrocytoma mimicking glioblastoma. Acta Cytol. 1999;43:652–8.
Korshunov A, Meyer J, Capper D, Christians A, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropath. 2009;118:401–5.
Parwani AV, Berman D, Burger PC, Ali SZ. Gliosarcoma: cytopathologic characteristics on fine-needle aspiration and intraoperative touch imprint. Diagn Cytopathol. 2004;30:77–81.
Prayson RA, Estes ML. Protoplasmic astrocytoma: A clinicopathologic study of 16 tumors. Am J Clin Pathol. 1995;103:705–9.
Rodriguez FJ, Scheithauer BW, Burger PC, Giannini C. Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol. 2010;34:147–60.
Roth J, Roach ES, Bartels U, Józwiak S, et al. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the international tuberous sclerosis complex consensus conference 2012. Pediatric Neurol. 2013;49:439–44.
Schindler G, Capper D, Meyer J, Janzarik W, et al. Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121:397–405.
Schwartzentruber J, Korshunov A, Liu XY, Jones DT, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482:226–31.
Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta W, Phillips JJ, Perry A. Diffuse midline gliomas with histone H3-K27 M mutation: A series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathology. 2016;26:569–80.
Takei H, Florez L, Bhattacharjee MB. Cytologic features of subependymal giant cell astrocytoma. A review of 7 cases. Acta Cytol. 2008;52:445–50.
Teo JG, Ng HK. Cytodiagnosis of pilocytic astrocytoma in smear preparations. Acta Cytol. 1998;42:673–8.
Venneti S, Santi M, Felicella MM, Yarilin D, et al. A sensitive and specific histopathologic prognostic marker for H3F3A K27 M mutant pediatric glioblastomas. Acta Neuropathol. 2014;128:743–53.
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149–53.
Weller M, Stupp R, Reifenberger G, Brandes AA, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev. Neurol. 2010;6:39–51.
Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature Genet. 2014;46:444–50.
Yan H, Parsons DW, Jin G, McLendon R, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–73.
Yue X, Liu X, Lo S. Diagnosis of astrocytomas in crush preparations. Acta Cytol. 1987;31:83–4.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lacruz, C.R., Saénz de Santamaría, J., Bardales, R.H. (2018). Astrocytic Tumors. In: Central Nervous System Intraoperative Cytopathology. Essentials in Cytopathology, vol 13. Springer, Cham. https://doi.org/10.1007/978-3-319-98491-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-98491-9_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-98490-2
Online ISBN: 978-3-319-98491-9
eBook Packages: MedicineMedicine (R0)